SCHEDULE: Baker Bros. Reduces KALA BIO Stake, Loses Board Rights

Baker Bros. Advisors LP and affiliates have reduced their beneficial ownership in KALA BIO, Inc. to 9.99%, resulting in the loss of their right to nominate directors to the company's Board.

Summary

• Reporting Persons, including Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, and Felix J. Baker, now beneficially own 744,759 shares of KALA BIO, Inc. Common Stock.
• This represents 9.99% of the Issuer's outstanding Common Stock, based on 7,021,040 shares as of August 7, 2025, plus convertible Series E Preferred shares.
• The filing reports sales of common stock that led to a more than 1% change in beneficial ownership.
• As a direct consequence of these sales, the Funds (Baker Brothers Life Sciences, L.P. and 667, L.P.) no longer possess the right to nominate individuals for election to KALA BIO's Board of Directors.
• The beneficial ownership includes 434,200 shares of Common Stock convertible from 4,342 Series E Preferred shares held directly by the Funds.
• The Funds also hold Series F, G, and H Preferred stock, convertible into Common Stock at a 1-to-100 ratio, subject to a 9.99% beneficial ownership limitation, which can be increased to 19.99% with 61 days' notice.
• Recent transactions include sales of 100,000 shares on September 27, 2025, at a weighted average price ranging from $1.50 to $1.84; 100,000 shares on September 26, 2025, at a weighted average price ranging from $1.27 to $1.48; and 100,000 shares on September 25, 2025, at a weighted average price ranging from $1.40 to $1.54.

Sentiment

Score: 3

Explanation: The reduction in beneficial ownership by a major institutional investor and the loss of board nomination rights are generally perceived as negative signals, suggesting a potential decrease in investor confidence or a strategic shift away from the company.

Negatives

• Baker Bros. Advisors LP and affiliates reduced their beneficial ownership in KALA BIO, Inc. to 9.99% from a previously higher stake.
• The reduction in ownership resulted in the loss of the Funds' right to nominate individuals to KALA BIO's Board of Directors, signaling reduced influence and potentially diminished strategic alignment.
• Significant sales of 300,000 shares of common stock occurred across three days in late September 2025, indicating a divestment trend by a major holder.

Risks

• The Reporting Persons may acquire or dispose of additional securities of KALA BIO in varying amounts and at varying times, depending on their assessment of factors such as business prospects, economic conditions, and stock market conditions, introducing uncertainty for other investors.
• Conversion of Series E, F, G, and H Preferred stock is subject to a 9.99% beneficial ownership limitation, which could restrict the full conversion of these shares into common stock if not managed carefully, although this limit can be increased to 19.99% with 61 days' notice.

Future Outlook

The Reporting Persons or their affiliates may acquire or dispose of additional securities of KALA BIO, Inc. in varying amounts and at varying times, based on continuous assessments of pertinent factors including business prospects, economic conditions, and stock market conditions. They may also discuss items of mutual interest with KALA BIO's Board, management, and other investors.

Industry Context

KALA BIO operates in the biotechnology sector, a field characterized by high R&D costs and significant investor interest in early-stage development. Baker Bros. Advisors is a prominent investor in the biotech space, and their decision to reduce their stake in KALA BIO could reflect a re-evaluation of the company's specific pipeline, market positioning, or broader portfolio rebalancing within the competitive biotech landscape.

Corporate Governance

Stakeholder Impact

• Shareholders: May perceive the reduction in a major investor's stake and the loss of board influence as a negative signal, potentially impacting stock price and investor confidence.
• Management/Board: Could face increased scrutiny or pressure due to a significant investor reducing their position and influence, potentially affecting strategic decision-making and investor relations.

Next Steps

• Reporting Persons may engage in further acquisitions or dispositions of KALA BIO securities based on their ongoing assessments of various market and company-specific factors.
• The Funds may increase their Beneficial Ownership Limitation for preferred stock conversion to any percentage not exceeding 19.99% by providing 61 days' notice to the Issuer.

Key Dates

Recommendation

The decision by Baker Bros. Advisors, a highly respected biotech investor, to significantly reduce its stake in KALA BIO and relinquish its board nomination rights is a strong negative signal. This action suggests a potential loss of confidence in the company's future prospects or a strategic reallocation of capital. Such a move by a major institutional holder typically precedes or accompanies downward pressure on the stock price, making a 'sell' recommendation prudent for investors seeking to mitigate risk or reallocate capital.

Keywords

KALA BIO, Baker Bros. Advisors, Beneficial Ownership, Schedule 13D, Common Stock, Preferred Stock, Biotech Investment, Shareholder Activity, Corporate Governance